The Food and Drug Administration today alerted health care providers to safety risks associated with cesium chloride, a mineral salt sometimes taken by cancer patients who seek alternative treatments. Reported adverse events included QT prolongation (a dangerous abnormality that can impair the heart’s ability to maintain a normal rhythm), low potassium, seizures, potentially lethal arrhythmias, fainting, cardiac arrest and death. FDA also said it intends to move cesium chloride to the category of substances that present significant safety risks in compounding. 

Related News Articles

Webinar Recordings
Member
Learn how a Patient Risk Assessment Profile allowed nurses to proactively assess patient risk to guide staffing decisions and nurse-patient assignment.…
Webinar Recordings
Member
Tuesday, August 6, 2019
Letter
Public
AHA encourages Congressional leaders to pass the Pandemic and All-Hazards Preparedness…
Issue Brief
How are value and health equity connected?
Letter
Public
Download the letter (PDF) below Re: CMS—3346—P, Medicare
Case Studies
In 2001, a Samaritan Health Services (SHS) physician, Dr. Richard Wopat, recognized the need to improve birth outcomes of high-risk pregnant women in the…